Literature DB >> 20663970

Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation.

Michael Edward1, Jean A Quinn, A David Burden, Ben B Newton, Alan G Jardine.   

Abstract

PURPOSE: To determine the ability of different types of gadolinium-based contrast agents (GBCAs) to stimulate fibroblast proliferation in monolayer cell culture.
MATERIALS AND METHODS: The National Health Service West Glasgow Ethics Committee granted approval for this study. Fibroblasts established from healthy volunteers (control subjects) and from lesional skin of patients with nephrogenic systemic fibrosis were exposed to a range of concentrations of ionic and nonionic linear and macrocyclic contrast agents over 4 days, and the effect on growth was determined. The lowest concentration of contrast agent that stimulated the maximum effect on fibroblast growth was selected for determination of its effect on fibroblast growth over 8 days. The effect of contrast agents on hyaluronan and collagen synthesis was determined with an enzyme-linked immunosorbent assay. Responses were assessed with analysis of variance (general linear model).
RESULTS: The linear gadolinium contrast agents (gadodiamide, gadoversetamide, gadopentetate dimeglumine, and gadobenate dimeglumine) produced a maximum stimulation of fibroblast proliferation at a concentration of 0.1 mmol/L, with cell numbers increasing up to 2.3-fold. The macrocyclic contrast agents (gadoteric acid and gadoteridol) produced a maximum stimulation of fibroblast proliferation at a concentration of 5 mmol/L. The reference gadolinium agents (N-methylglucamine gadolinium ethylenediaminetetraacetic acid and gadolinium trichloride) stimulated fibroblast proliferation at a concentration of 0.01 mmol/L and were toxic at a concentration greater than 1 mmol/L. Growth curves supported the dose-response observations. Hyaluronan synthesis was stimulated by gadoversetamide, gadobenate dimeglumine, gadodiamide, and gadopentetate dimeglumine at a concentration of 0.1 mmol/L and by gadolinium trichloride at a concentration of 0.01 mmol/L, whereas collagen synthesis was unaffected.
CONCLUSION: This study provides evidence that different classes of gadolinium chelates stimulate human fibroblast proliferation. (c) RSNA, 2010.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20663970     DOI: 10.1148/radiol.10091131

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  21 in total

Review 1.  Gadolinium and nephrogenic systemic fibrosis: have the alarm bells been silenced?

Authors:  O Tamburrini; A Balducci
Journal:  Radiol Med       Date:  2011-10-21       Impact factor: 3.469

2.  Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis.

Authors:  Bruce L Riser; Narasimharao Bhagavathula; Patricia Perone; Kendra Garchow; Yiru Xu; Gary J Fisher; Feridoon Najmabadi; Durga Attili; James Varani
Journal:  J Cell Commun Signal       Date:  2012-05-31       Impact factor: 5.782

3.  Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis.

Authors:  Peter J Wermuth; Sergio A Jimenez
Journal:  J Immunol       Date:  2012-05-30       Impact factor: 5.422

4.  Stimulation of fibroblast proliferation by insoluble gadolinium salts.

Authors:  Katherine Bleavins; Patricia Perone; Madhav Naik; Muneeb Rehman; Muhammad N Aslam; Michael K Dame; Sasha Meshinchi; Narasimharao Bhagavathula; James Varani
Journal:  Biol Trace Elem Res       Date:  2011-09-01       Impact factor: 3.738

Review 5.  Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals.

Authors:  Hisataka Kobayashi; Michelle R Longmire; Mikako Ogawa; Peter L Choyke
Journal:  Chem Soc Rev       Date:  2011-05-23       Impact factor: 54.564

Review 6.  The Impact of Excess Ligand on the Retention of Nonionic, Linear Gadolinium-Based Contrast Agents in Patients With Various Levels of Renal Dysfunction: A Review and Simulation Analysis.

Authors:  John P Prybylski; Michael Jay
Journal:  Adv Chronic Kidney Dis       Date:  2017-05       Impact factor: 3.620

7.  Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents.

Authors:  P J Wermuth; S A Jimenez
Journal:  Clin Exp Immunol       Date:  2014-01       Impact factor: 4.330

8.  Fibroblast response to lanthanoid metal ion stimulation: potential contribution to fibrotic tissue injury.

Authors:  William Jenkins; Patricia Perone; Kyle Walker; Narasimharao Bhagavathula; Muhammad Nadeem Aslam; Marissa DaSilva; Michael K Dame; James Varani
Journal:  Biol Trace Elem Res       Date:  2011-04-12       Impact factor: 3.738

9.  Distribution of estimated glomerular filtration rate (eGFR) values in patients receiving contrast-enhanced magnetic resonance imaging.

Authors:  Keigo Shimoji; Shigeki Aoki; Atsushi Nakanishi; Michimasa Suzuki; Masaaki Hori; Syuji Sato; Haruyoshi Hoshito; Shinsuke Kyogoku; Narisumi Cho; Yutaka Ozaki; Masaru Suzuki; Ryohei Kuwatsuru; Keisuke Sasai
Journal:  Jpn J Radiol       Date:  2011-12-27       Impact factor: 2.374

10.  Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents.

Authors:  Emmanuil Smorodinsky; David S Ansdell; Zeke W Foster; Sameer M Mazhar; Irene Cruite; Tanya Wolfson; Sebastian B Sugay; Gabriella Iussich; Masoud Shiehmorteza; Yuko Kono; Alexander Kuo; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2014-05-09       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.